Yanna Lei Sha Zhao Ming Jiang
10.3389/fimmu.2021.653319
Front Immunol
2021 Sep 8;12:653319.
antiangiogenesis follicular dendritic cell sarcoma immune checkpoint inhibitor lenvatinib sintilimab
CC BY
https://pubmed.ncbi.nlm.nih.gov/34566950/
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Dendritic Cell Sarcoma, Follicular / drug therapy Immune Checkpoint Inhibitors / therapeutic use Intestinal Neoplasms / drug therapy Phenylurea Compounds / therapeutic use Quinolines / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Dendritic Cell Sarcoma, Follicular / drug therapy Immune Checkpoint Inhibitors / therapeutic use Intestinal Neoplasms / drug therapy Phenylurea Compounds / therapeutic use Quinolines / therapeutic use Case Reports Review Antibodies, Monoclonal, Humanized / therapeutic use Humans Male Middle Aged Salvage Therapy / methods Antibodies, Monoclonal, Humanized Immune Checkpoint Inhibitors Phenylurea Compounds Quinolines sintilimab lenvatinib
PMC8456086
34566950
Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review
2021